New therapeutic perspectives in CCDC6 deficient lung cancer cells

Nucleotide excision repair: Why is it not used to predict response to platinum-based chemotherapy?

(2014) Nikola A. Bowden   CANCER LETTERS

Critical role of CCDC6 in the neoplastic growth of testicular germ cell tumors

(2013) Stefania Staibano et al.   BMC CANCER

Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models

(2013) Kiyoshi Okamoto et al.   CANCER LETTERS

Rationale and Design of MILES-3 and MILES-4 Studies: Two Randomized Phase 3 Trials Comparing Single-Agent Chemotherapy Versus Cisplatin-Based Doublets in Elderly Patients With Advanced Non–Small-Cell Lung Cancer

(2013) Cesare Gridelli et al.   Clinical Lung Cancer

The PI3K/AKT pathway promotes gefitinib resistance in mutantKRASlung adenocarcinoma by a deacetylase-dependent mechanism

(2013) Victor Jeannot et al.   INTERNATIONAL JOURNAL OF CANCER

Detection of Impaired Homologous Recombination Repair in NSCLC Cells and Tissues

(2013) Moritz Birkelbach et al.   Journal of Thoracic Oncology

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

(2013) Shahneen K Sandhu et al.   LANCET ONCOLOGY

Targeted DNA methylation by homology-directed repair in mammalian cells. Transcription reshapes methylation on the repaired gene

(2013) A. Morano et al.   NUCLEIC ACIDS RESEARCH

A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer

(2013) S Postel-Vinay et al.   ONCOGENE

The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells

(2013) Silvana B. De Lorenzo et al.   Frontiers in Oncology

PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells

(2012) H. Cheng et al.   CARCINOGENESIS

Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing

(2012) Marcin Imielinski et al.   CELL

Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment

(2012) Lenka Oplustilova et al.   CELL CYCLE

FBXW7-mediated degradation of CCDC6 is impaired by ATM during DNA damage response in lung cancer cells

(2012) Zhao JunGang et al.   FEBS LETTERS

Identification of CCDC6-RET Fusion in the Human Lung Adenocarcinoma Cell Line, LC-2/ad

(2012) Daisuke Matsubara et al.   Journal of Thoracic Oncology

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

(2012) D Ross Camidge et al.   LANCET ONCOLOGY

RET, ROS1 and ALK fusions in lung cancer

(2012) Kengo Takeuchi et al.   NATURE MEDICINE

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Loss of CCDC6, the First Identified RET Partner Gene, Affects pH2AX S139 Levels and Accelerates Mitotic Entry upon DNA Damage

(2012) Francesco Merolla et al.   PLoS One

Biomarker studies: a call for a comprehensive biomarker study registry

(2011) Fabrice Andre et al.   Nature Reviews Clinical Oncology

GADD45α inhibition of DNMT1 dependent DNA methylation during homology directed DNA repair

(2011) Bongyong Lee et al.   NUCLEIC ACIDS RESEARCH

DNA Methyltransferase 1-associated Protein (DMAP1) Is a Co-repressor That Stimulates DNA Methylation Globally and Locally at Sites of Double Strand Break Repair

(2010) Gun E. Lee et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC

(2010) Alex Chang   LUNG CANCER

CCDC6 represses CREB1 activity by recruiting histone deacetylase 1 and protein phosphatase 1

(2010) V Leone et al.   ONCOGENE

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Defining the Human Deubiquitinating Enzyme Interaction Landscape

(2009) Mathew E. Sowa et al.   CELL

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity

(2008) Christopher J. Lord et al.   DNA REPAIR

Comparison of nonhomologous end joining and homologous recombination in human cells

(2008) Z MAO et al.   DNA REPAIR

A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair

(2008) Alan Ashworth   JOURNAL OF CLINICAL ONCOLOGY

EGFR Antagonists in Cancer Treatment

(2008) Fortunato Ciardiello et al.   NEW ENGLAND JOURNAL OF MEDICINE

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

(2008) S. Rottenberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA